ID: ALA162743

Max Phase: Preclinical

Molecular Formula: C21H22BrNO3

Molecular Weight: 416.32

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc2c(c1)c(C(C)CC(=O)O)c(C)n2Cc1ccc(Br)cc1

Standard InChI:  InChI=1S/C21H22BrNO3/c1-13(10-20(24)25)21-14(2)23(12-15-4-6-16(22)7-5-15)19-9-8-17(26-3)11-18(19)21/h4-9,11,13H,10,12H2,1-3H3,(H,24,25)

Standard InChI Key:  ZGLPWVFYTARBPC-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 416.32

Molecular Weight (Monoisotopic): 415.0783

AlogP: 5.35

#Rotatable Bonds: 6

Polar Surface Area: 51.46

Molecular Species: ACID

HBA: 3

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 4.43

CX Basic pKa:

CX LogP: 5.20

CX LogD: 2.34

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.59

Np Likeness Score: -0.48

References

1. Black W, Bayly C, Belley M, Chan C, Charleson S, Denis D, Gauthier J, Gordon R, Guay D, Kargman S, Lau C, Leblanc Y, Mancini J, Ouellet M, Percival D, Roy P, Skorey K, Tagari P, Vickers P, Wong E, Xu L, Prasit P.  (1996)  From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors,  6  (6): [10.1016/0960-894X(96)00100-X]

Source

Source(1):

• Scientific Literature